Coating of Stent With Bactiguard Reduces Acute Stent Thrombosis

The medical and technology teams at Bactiguard, in collaboration with Sweden's KTH, the country's largest technical university (Division of Micro and Nanosystems), and the Karolinska Institute (Department of Clinical Neuroscience), conducted a study //on the impact of Bactiguard's noble metal coating in reducing thrombo-inflammatory reactions and acute stent thrombosis (1^✔ ✔Trusted Source
Bactiguard's coating reduces thrombo-inflammatory reactions and acute stent thrombosis

Go to source).

Bactiguard's Remarkable Anti-Microbial and Anti-Thrombo-Inflammatory Properties

Bactiguard is an international medical technology company specializing in the development of antibacterial, biocompatible, and safe technologies and solutions designed to prevent infections related to medical devices in five distinct therapeutic areas: orthopedics, urology, intravascular/critical care, dental, and wound care. Any medical device inserted into the bloodstream triggers a thrombo-inflammatory reaction, including coagulation system activation that can potentially lead to thrombosis. Stents, which are metal nets designed to open obstructed blood vessels, can lead to serious complications if they activate the coagulation system and thrombosis forms within the stent, potentially causing injury or even death.

Bactiguard's noble metal coating has a unique property that reduces microbial adhesion to the surface of medical devices. Previous studies have hinted at its ability to reduce thrombo-inflammatory reactions.

This particular study was conducted to gather more clinical data and evidence regarding the coating's effectiveness. For innovation and future application development, two versions of the coating were applied to the stents in the study: Bactiguard's "standard" coating consisting of gold, silver, and palladium, and a modified version including neodymium.

The study used both in vivo (in pigs) and in vitro methods (blood marker analysis, including human samples). Pigs underwent blinded implantation of both coated and non-coated stents, with the interventionist unaware of which stents were coated. The experiment concluded after two hours, representing the acute implantation phase.

Stents were placed in the lingual artery, with one coated and one uncoated on each side. CT-scan data was used to analyze stent volume, performed by an assessor blinded to the treatment. Laboratory tests were conducted using both human and pig blood, with all human participants providing consent.

Measurements revealed that the coated stent group exhibited a significant reduction in blood clot volume compared to the control group. This effect was noticeable as early as one hour after stent implantation and became more pronounced after two hours. In vitro data, using both human and pig blood, showed a marked decrease in coagulation and inflammation markers in the coated group compared to the control group.

Advertisement

Dr. Stefan Grass, Chief Medical Officer at Bactiguard, commented, "The findings of this study are promising and provide crucial data supporting the efficacy of Bactiguard's coating. The combination of infection prevention without an increased risk of thrombosis is highly appealing and unique for a coated intravascular device."

Reference:

1. Bactiguard's coating reduces thrombo-inflammatory reactions and acute stent thrombosis - (https://www.prnewswire.com/news-releases/bactiguards-coating-reduces-thrombo-inflammatory-reactions-and-acute-stent-thrombosis--new-study-published-301954683.html)

Source-Medindia